Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 558 of 5804
-
New combo aims to supercharge standard thyroid cancer therapy
Disease control Recruiting nowPapillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung meta…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a rheumatoid arthritis drug save lung transplants?
Disease control Recruiting nowThis is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppressio…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a mild zap to the brain help you find your words?
Symptom relief Recruiting nowWhile many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap i…
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy targets untreatable liver cancer
Disease control OngoingThe purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenabl…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to stop brain cancer growth in older patients
Disease control Recruiting nowThis study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the us…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
MDMA boosts PTSD therapy in quick 10-Day program
Symptom relief ENROLLING_BY_INVITATIONPosttraumatic stress disorder (PTSD) is a debilitating disorder. While effective treatments exist, some patients fail to receive the full benefits. Alternative treatment approaches are needed. 3,4-methylenedioxymethamphetamine (MDMA) is a medicine associated with feelings of clos…
Phase: PHASE2 • Sponsor: Emory University • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New hope for inoperable bile duct cancer: targeted therapies aim to shrink tumors
Disease control Recruiting nowPatients with intrahepatic cholangiocarcinoma (IHC) have relatively aggressive tumors, and the prognosis for most of these patients is dismal. Surgery is the only option that can offer potential cure, but only an estimated 20-25 % are amenable to resection. Down-staging conventio…
Phase: PHASE2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Triple therapy takes on bile duct cancer: hope for unresectable cases
Disease control Recruiting nowThis trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of ra…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
Disease control Recruiting nowThis is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics,…
Phase: PHASE1, PHASE2 • Sponsor: Alyssum Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThe goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose level…
Phase: PHASE1, PHASE2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a common antibiotic stop pneumonia from turning deadly?
Disease control Recruiting nowThe primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by su…
Phase: PHASE3 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Balloon in the womb: new hope for babies with rare birth defect?
Disease control Recruiting nowThis is a single site pilot trial to assess the feasibility and safety of treating severe CDH with Fetal Endoscopic Tracheal Occlusion with the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) at UC Davis Medical Center. The study…
Phase: NA • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Could a yeast vaccine stop Cancer's return?
Disease control Recruiting nowThis is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between t…
Phase: PHASE2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New cholera drug could cut antibiotic use and hospital stays
Disease control CompletedCholera still remains a global public health concern affecting both children and adults, and patients can succumb in quick time if remain untreated. Cholera is a secretory diarrhea and is generally treated with oral or intravenous rehydration therapy to compensate for the fluid l…
Phase: PHASE2 • Sponsor: Hunazine Biotech S.L. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Engineered immune cells take on lupus in early trial
Disease control OngoingThis is an investigator-initiated trial aimed at assessing the safety of anti-CD19 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New device aims to pull clots from the brain in major strokes
Disease control CompletedThe study aims to evaluate the safety and efficacy of the Supernova stent retriever device, developed by Gravity Medical Technology, for treating acute ischemic stroke. The device is used to remove blood clots and restore blood flow to the brain .
Phase: NA • Sponsor: Gravity Medical Technology, INC • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThe purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other pla…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
HIV breakthrough trial seeks to rescue failing treatments in africa
Disease control Recruiting nowThe RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir (TLD) in sub-Saharan Africa. The primary outcome of …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Clot removal may boost recovery in mild stroke patients
Disease control Recruiting nowPatients presenting with mild symptoms of acute ischemic stroke are common and account for approximately half of all acute ischemic stroke. About 30% of patients with minor stroke have a 90-day functional disability. Radiologically proven a large vessel occlusion (LVO) in patient…
Phase: NA • Sponsor: First Affiliated Hospital of Wannan Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC